hsa-mir-8063: Hsa-mir-8063 is a microRNA that has been identified as a novel biomarker for the progression of gestational diabetes mellitus (GDM) [PMC8145272]. It has also been found to be differentially expressed in the blood of colorectal cancer patients who developed venous thromboembolism (VTE) [PMC9361765]. In addition, hsa-mir-8063 has been implicated in promoting colorectal cancer (CRC) through its binding potential with the long non-coding RNA CCAT1 [PMC8739552]. It is also predicted to interact with hsa_circRNA_000102, along with several other miRNAs and mRNAs [PMC7388456]. Furthermore, hsa-mir-8063 has been shown to inhibit pancreatic cancer progression by targeting ZFP91 [PMC9455708]. Overall, hsa-mir-8063 is a microRNA that has been implicated in various diseases and biological processes. Its differential expression in GDM and its potential as a biomarker for disease progression highlight its importance in understanding and managing this condition. Its involvement in CRC and pancreatic cancer suggests its potential as a therapeutic target for these malignancies. Further research is needed to fully elucidate the mechanisms by which hsa-mir-8063 functions and its potential clinical applications. References: [PMC8145272] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145272/ [PMC9361765] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361765/ [PMC8739552] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739552/ [PMC7388456] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388456/ [PMC9455708] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455708/